The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

In a milestone in mammalian genetic engineering, a team of researchers from the Chinese Academy of Sciences succeeded in ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.A novel ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...